ALNY Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 441 min ago

@ $152.10

Wydano: 3 geg. 2024 @ 16:30

Zwrot: 0.15%

Poprzedni sygnał: geg. 2 - 16:33

Poprzedni sygnał: Kupno

Zwrot: 1.95 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference...

Stats
Dzisiejszy wolumen	440 176
Średni wolumen	834 624
Kapitalizacja rynkowa	19.26B
EPS	$0 ( 2024-05-02 )
Następna data zysków	( $-1.180 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-43.28
ATR14	$3.48 (2.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Fitzgerald Kevin Joseph	Sell	0	Common Stock
2024-03-20	Fitzgerald Kevin Joseph	Buy	0	Common Stock
2021-02-11	Fitzgerald Kevin Joseph	Sell	9 000	Performance Stock Option 2017 (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	16 250	Stock Option (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	6 667	Stock Option (right to buy)

INSIDER POWER
-6.10
Last 99 transactions
Buy: 237 064 \| Sell: 275 392

Wolumen Korelacja

Długi: 0.00 (neutral)

Krótki: -0.72 (moderate negative)

Signal:(38) Neutral

Alnylam Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
KRNY	0.958
INDB	0.956
MRBK	0.955
CYXT	0.951
RVSB	0.95
HAFC	0.949
BMRC	0.948
DCOM	0.947
MNSB	0.945
CBNK	0.945

10 Najbardziej negatywne korelacje
IIN	-0.943
THRX	-0.942
MYNA	-0.939
ALXN	-0.936
BRAC	-0.934
ICVX	-0.933
KRTX	-0.932
TA	-0.931
FLXS	-0.928
ECHO	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alnylam Pharmaceuticals Korelacja - Waluta/Towar

0.19
( neutral )

0.17
( neutral )

0.00
( neutral )

0.24
( neutral )

-0.32
( neutral )

0.15
( neutral )

Alnylam Pharmaceuticals Finanse

Annual	2023
Przychody:	$1.83B
Zysk brutto:	$1.52B (83.02 %)
EPS:	$-3.52

FY	2023
Przychody:	$1.83B
Zysk brutto:	$1.52B (83.02 %)
EPS:	$-3.52

FY	2022
Przychody:	$1.04B
Zysk brutto:	$868.60M (83.73 %)
EPS:	$-9.30

FY	2021
Przychody:	$844.29M
Zysk brutto:	$704.14M (83.40 %)
EPS:	$-7.20

Financial Reports:

No articles found.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.